Wouldn't both reduced patent protections and price controls reduce incentive to invest in R&D and for private investors likewise reduce incentive to invest in p

Wouldn't both reduced patent protections and price controls reduce incentive to invest in R&D and for private investors likewise reduce incentive to invest in pharma that invests in R&D?